Options
Coinage Metal NHC Complexes as Novel Antibiotics and Anticancer Drugs
Author(s)
Date Issued
2017-06-09
Date Available
2019-05-07T12:49:24Z
Abstract
The synthesis and biological evaluation against cancer cells and pathogenic bacteria as well as fungi of five coinage metal NHC complexes derived from copper (WBC4), silver (SBC1/SBC3) and gold (NHC-Au-Cl/NHC-Au-SR) is reviewed. The NHC ligand for these compounds is 1,3-dibenzyl-4,5-diphenylimidazol-2-ylidene or derivatives closely related, since this ligand is proven suitable for drug-like molecules. The NHC-silver acetate complex SBC1 failed as an anticancer drug candidate in vivo, while its highly related compound SBC3 succeeded in vivo as an experimental antibiotic in Galleria mellonella larvae showing survival advantage against pathogenic bacteria and fungi. The corresponding gold complexes of NHC-Au-Cl and NHC-Au-SR (R = thioglucoside) as well as the NHC-copper bromide derivative WBC4 exhibited significant growth inhibition, when tested against xenografted human renal-cell cancer Caki-1 in nude mice; WBC4 showed tolerable toxicity in the form of reversible body weight loss, while the two gold compounds did not induce body weight loss in the xenograft mouse model experiment.
Sponsorship
University College Dublin
Other Sponsorship
National Cancer Institute in Maryland (USA)
Type of Material
Conference Publication
Publisher
Slovak University of Technology Publishing House
Series
Volume 13
Copyright (Published Version)
2017 Slovak Chemical Society
Web versions
Language
English
Status of Item
Not peer reviewed
Part of
MelnÃk, M., Segľa, P., Tatarko, M. (eds.). Modern Trends in Coordination, Bioinorganic, and Applied Inorganic Chemistry
Conference Details
The 26th International Conference on Coordination Chemistry (26th ICCBiC), Smolenice, Slovakia, 4-9 June 2017
ISBN
978-80-89597-65-9
ISSN
1335-308X
This item is made available under a Creative Commons License
File(s)
Owning collection
Views
769
Acquisition Date
Apr 16, 2024
Apr 16, 2024
Downloads
122
Last Month
2
2
Acquisition Date
Apr 16, 2024
Apr 16, 2024